# A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

> **NCT06315322** · PHASE3 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 120 (estimated)

## Conditions studied

- Childhood Absence Epilepsy
- Juvenile Absence Epilepsy

## Interventions

- **DRUG:** Brivaracetam Film-coated tablet
- **DRUG:** Brivaracetam oral solution

## Key facts

- **NCT ID:** NCT06315322
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2030-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315322, "A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06315322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*